within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A04A_AntiemeticsAndAntinauseants.A04AA01_Ondansetron;

model Ondansetron_1
  extends Pharmacolibrary.Drugs.ATC.A.A04AA01_1;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A04AA01_1</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ondansetron is a selective serotonin 5-HT3 receptor antagonist used primarily as an antiemetic to prevent nausea and vomiting caused by cancer chemotherapy, radiotherapy, and surgery. It is approved and widely used internationally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following intravenous administration in healthy adults; parameters reflect standard IV dosing.</p><h4>References</h4><ol><li><p>Sotelo, CK, et al., &amp; Zersen, KM (2022). Pharmacokinetics and anti-nausea effects of intravenous ondansetron in hospitalized dogs exhibiting clinical signs of nausea. <i>Journal of veterinary pharmacology and therapeutics</i> 45(6) 508–515. DOI:<a href=\"https://doi.org/10.1111/jvp.13087\">10.1111/jvp.13087</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35899472/\">https://pubmed.ncbi.nlm.nih.gov/35899472</a></p></li><li><p>Quimby, JM, et al., &amp; Gustafson, DL (2014). Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats. <i>Journal of veterinary pharmacology and therapeutics</i> 37(4) 348–353. DOI:<a href=\"https://doi.org/10.1111/jvp.12094\">10.1111/jvp.12094</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24330064/\">https://pubmed.ncbi.nlm.nih.gov/24330064</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Ondansetron_1;
